RACC Research Alliance Corp III
Pharmaceutical Preparations · Nasdaq · SEC CIK 2118032 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets8.7%
Debt / equity—
Current ratio0.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| SG&A expense | $977,793 | $184,418 |
| Operating income | -$977,793 | -$184,418 |
| Net income | -$1.95M | $54,050 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $183,405 | $832,812 |
| Current assets | $312,054 | $961,461 |
| Total assets | $78.90M | $76.31M |
| Current liabilities | $2.91M | $55,587 |
| Total liabilities | $6.85M | $2.31M |
| Shareholders' equity | -$3.90M | -$1.24M |
| Cash flow statement | ||
| Operating cash flow | — | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.